June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

June 21, 2016

Survey of Patients with Psoriasis, Other Diseases, Identifies Knowledge Gaps About Biosimilars

News

Researchers at Pfizer conducted a survey on the knowledge, awareness, and usage of biosimilars among caregivers, patients — including psoriasis patients — and the general population in the U.S. and ... Read more

June 20, 2016

Serious Infections More Prevalent in Inpatients with Psoriasis, Related to Higher Costs and Longer Hospital Stays

News

Researchers at Northwestern University’s Feinberg School of Medicine investigated the rates and predictors of serious infections in hospitalized patients with psoriasis and also quantified the costs of their care, length ... Read more

June 17, 2016

EU Grants Clinical Trial Approval for Plaque Psoriasis Phase 3 Study of ONS-3010 (Humira Biosimilar)

News

Cranbury, New Jersey-based Oncobiologics announced that its Phase 3 clinical strategy for ONS-3010 (Humira biosimilar) has been granted the first of its European Union (EU) clinical trial authorization (CTA) approvals, including Spain, Germany, and ... Read more

June 16, 2016

Can-Fite to Report New Data on Piclidenoson, a Biologic to Treat Psoriasis, at Paris Congress

News

Can-Fite BioPharma, Ltd., announced that its lead drug candidate, Piclidenoson (CF101), has shown similar anti-inflammatory efficacy to the biologics currently on the market for the treatment of psoriasis, with the ... Read more

June 15, 2016

Life Course Approach May Improve Understanding, Management of Psoriasis, Other Chronic Skin Diseases

News

A multi-disciplinary team of researchers conducted a study with the goal of raising the profile of the life course approach, a sociology research tool used in increasing popularity in health research ... Read more

June 14, 2016

Psoriasis Study Finds Cognitive Behavioral Approach Helps Quality of Life, Reduces Disease Severity

News

Researchers recently evaluated the usefulness of psychosocial interventions in patients with psoriasis and found them to be beneficial, improving their quality of life and reducing the disease’s clinical severity. The ... Read more

June 13, 2016June 13, 2016

New Drug to Treat Psoriasis, Ixekizumab, Seen to Aid Almost 80% of Patients in Clinical Trials

News

Three pivotal clinical trials assessing ixekizumab report that the drug is highly effective in treating moderate to severe psoriasis in a majority of patients. The findings, which led to the drug’s approval, are detailed in the study “Phase ... Read more

June 9, 2016

Researchers Find Potential Psoriasis Therapeutic Target in B-Cells and Their Role in Inflammation

News

Researchers focused on B-cells and their possible role in the inflammation characteristic of psoriasis and identified a protein that may constitute a potential therapeutic target to treat the disease. The ... Read more

June 8, 2016

Review Study Finds Strong Link Between Smoking and Development of Psoriasis

News

The association between tobacco smoking and the onset of psoriasis was recently reviewed in a study, “Psoriasis and smoking: links and risks,” published in Psoriasis: Targets and Therapy. Tobacco smoke ... Read more

June 7, 2016

In Psoriasis and Psoriatic Arthritis Patients, Biologics Therapy Seems to Help Depression and Insomnia

News

Researchers at several Chinese medical and research institutions investigated the effects of biologics therapy — namely tumor necrosis factor inhibitors — on the psychological symptoms and well-being of psoriasis patients, and found ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata